Uh-oh, looks like you've been reading the liars on lieHUB

New Post Public Reply Private Reply Replies (2) Message Board
Drano petemantx #38113
365
Uh-oh, looks like you've been reading the liars on lieHUB and have let them convince you that things were said that were in fact NOT said.

Where does the company ever refer to Brilacidin as a "franchise drug"? What does that even mean?

Here's what I think makes sense (and of course this is just in my opinion):

Brilacidin has shown so far to be an incredibly powerful drug with few side effects. It's not absorbed significantly in the body when used for ulcerative proctitis. It has both antibiotic and anti-inflammatory properties. There are 3 clinical trials for 3 very different applications, all of which have been successful thus far.

Now: if you were a big pharma, would you want to buy the rights to market Brilacidin for Oral Mucositis, in its oral rinse form -- knowing that at some time some other company might buy the rights for Brilacidin oral rinse for dental infection? NO you would not. People might then buy that and use it off-label for oral mucositis.

That's just an example. A company would have to be crazy to license this drug for ONE use, knowing that other delivery platforms might be developed for other diseases, but might be used off-label for the use you licensed. What if it turns out that intravenous Brilacidin stops oral mucositis AND other side effects of chemo? (that's an example which I think is totally UNlikely -- just given as a "what if." )

You've seen the TV ads for all kinds of drugs. What big pharma would want to take out a TV ad for Brilacidin-OM, knowing that their competitor was marketing Brilacidin-UP? Answer: no one.

So, I do not think that a big pharma would want to make a deal for just one version of Brilacidin for one disease. And I don't think Leo would want to do that, because he knows that it would hurt the chances of licensing it for other things. I find it difficult to believe that there can be anything but a licensing of ALL forms of Brilacidin, to one company.

Leo has stated that he wants IPIX to be a ROYALTY company. Despite whatever scare tactics the bashers are trying to spew out, there is NO way that Leo is going to outright-sell Brilacidin. That would be stupid thing to do, unless someone bought the whole company. Leo is far from stupid, and he is the largest shareholder in the company. The most likely deal would be an upfront payment, and then ROYALTIES (probably 10-20%) on the sales of Brilacidin products. This would include ALL forms of Brilacidin, so if some other use comes up that we don't know about now, we'd still get royalties.

Do not believe the lies that those jerks are cranking out. They have spent the past couple of years suppressing the price, and screaming "Leo, make a deal, any deal" (that's an exact quote from one of them). Why do they want him to make a crappy deal? Because that's what the people behind the attack on the company want.... in my opinion.

Leo is NOT going to be a sucker and take some crap deal. He knows that Brilacidin is worth a huge amount, and he's going to get a good deal for the company. THAT'S why he did the shelf registration -- if some company wants to keep holding out for a deal that would cheat us, Leo's not going to take it. We'll just keep developing the drugs ourselves.



Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luxury Air Celebrates 18 Years of Comfort Service

Updated Category News Views 2

Celebrating 18 Years: A Journey of Comfort It's not often you see a business weave itself so seamlessly into the fabric of its community. But that's exactly what Luxury Air A/C & Heating has done in Conroe, The Woodlands, and across Montgomery County. Hit 18 years in the HVAC game, and you've clearly nailed something other folks can't quite replicate. Guess there's no...

Continue Reading
TriStar Bank Community Room: A Space for Growth

Updated Category News Views 1

Building Bridges Through Community Investment Well, ain't this something? Columbia, Tennessee, just got a splash of fresh air. We're talking about the new Southern Regional Technology Center nested in Columbia State Community College. Now, the name on everyone's lips? The TriStar Bank Community Room. But it ain't just about a name plastered up on a wall inside a shiny...

Continue Reading
BMO Sheds U.S. Branches, Eyes Strategic Growth

Updated Category News Views 1

Why BMO is Slimming Down in the States You know, when a heavyweight like BMO Financial Group starts shedding branches left and right, you gotta ask yourself what the grand plan is. In a move that looks more like a strategic dance than an abrupt U-turn, BMO's gotten rid of 138 U.S. branches, handing them over to First-Citizens Bank. We're talking outlets scattered from...

Continue Reading
Primero Gains Global Edge with Win Systems Buy

Updated Category News Views 2

Here's the move: Primero Games, the U.S.-based gaming maestro, just grabbed a hefty piece of the puzzle with their acquisition of Win Systems' Gaming Division. Not two companies merging into obscurity, but a strategic maneuver aiming to scatter new seeds in Latin America and the Caribbean with over 3,000 gaming positions primed and ready. What's in the Pot? You've got...

Continue Reading
SIAL West Asia Ignites Global F&B Trade at Guangzhou

Updated Category News Views 0

A Convergence of Global Taste You could feel the buzz in the air as the 2026 SIAL West Asia International Food Exhibition kicked off at the Guangzhou Poly World Trade Center Expo. Throw over 1,500 exhibitors from the far corners of the globe into a sprawling 60,000-square-meter trade floor, and you've got yourself a melting pot of flavors and cultures revolving around a...

Continue Reading
EF English Live's Approach to Workplace Confidence

Updated Category News Views 3

Pioneering English Confidence for the Global Workplace Stepping into a meeting with international partners requires more than just textbook knowledge of English. It's about confidently expressing ideas, adapting on the fly, and engaging with global colleagues. Enter EF English Live, a leader in transforming workplace communication through targeted English learning. Expert...

Continue Reading
PerfectVape Unveils Online Deals Amid Vape Craze

Updated Category News Views 3

PerfectVape's Digital Bargain Bonanza Alright, so you think you've seen savings? Well, PerfectVape's throwing a real bone to those hunting for vape deals online. They're slapping 10% off on select disposable vapes—no strings, just a promo code, PV10, you punch in at checkout. We've got ourselves an internet-era sale without needing to elbow through crowds. Browsing Made...

Continue Reading
Raiders' Telenovela Hype Ignites Passion in Mexico

Updated Category News Views 1

Raider Nation's Heart Beats in Mexico Hell, you ever see a football game that feels like a soap opera? You bet your boots that's exactly what the Raiders are cooking down in Mexico City. We're not talking about just any ol' season opener; it's the curtain call of Corazón de Plata y Negro. This ain't your average fanfare—it's a spectacle teeming with raw, unfiltered...

Continue Reading
Tech Job Market Surges: 86,000 Hires in August Boost

Updated Category News Views 2

Tech Job Growth Defies Corporate Layoffs Job markets in the tech world are hotter than a two-dollar pistol. Despite seeing some layoffs in tech firms, the demand for skilled tech workers is still booming. You got tech companies tightening the bolts, laying off around 14,700 folks, but here's the kicker: overall tech employment shot up with 86,000 new jobs in August....

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading

Top 5 Most Recently Viewed Articles

Ohana Real Estate Investors: Honored as Top Hotel Group in 2026

Updated Category News Views 300

A Stellar Achievement in Hospitality Just when you think the hotel industry can't get any more competitive, Ohana Real Estate Investors goes and bags the "Hotel Ownership Group of the Year" from the Forbes Travel Guide at their Summit in Monaco. This isn’t just a trophy on a mantle; it's a serious nod from the big players at CBRE and FTG, recognizing years of solid...

Continue Reading
Ionis Pharmaceuticals Sells $500 Million in Stock Offering

Updated Category News Views 126

Ionis Pharmaceuticals Unveils Major Stock Offering Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has announced a significant financial move involving a public offering of common stock. This underwritten offering includes 11,500,000 shares, each priced at $43.50, with total gross proceeds projected to reach an impressive $500.3 million. The funds raised are intended to...

Continue Reading
BPCE SFH's Strategic Restructuring for Noteholders Ahead

Updated Category News Views 105

Notice to Noteholders from BPCE SFH Notice to Noteholders To: Noteholders From: BPCE SFH 7, promenade Germaine Sablon 75013 Paris Copy: Fiscal Agent, Principal Paying Agent, and Calculation Agent: BNP Paribas Securities Services Les Grands Moulins de Pantin 9 rue du Débarcadère 93500 PANTIN BPCE SFH (“Issuer”) Legal Entity Identifier (LEI): 969500T1UBNNTYVWOS04...

Continue Reading
IMUNON Highlights Progress in Ovarian Cancer Treatment Plans

Updated Category News Views 109

Company Overview IMUNON, Inc. (Nasdaq: IMNN) is a clinical-stage biotechnology company dedicated to advancing innovative cancer therapies that leverage the body's natural defenses. The company focuses on developing a range of pioneering treatments utilizing their non-viral DNA technology platform. Recent Financial Results In its second quarter of 2025, IMUNON reported a...

Continue Reading
Supernus Pharmaceuticals Announces Q3 Earnings Call Details

Updated Category News Views 34

Supernus Pharmaceuticals Plans Third Quarter Earnings Call Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a leading biopharmaceutical company, is excited to share details about their upcoming conference call to discuss financial results for the third quarter of 2024. This event is set to take place shortly after the market closes, scheduled for November 4, 2024. Overview...

Continue Reading